SCHEMBL4149984

SCHEMBL4149984

NC(=O)Cc1ccc(F)c(O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.53
MEP1B Q16820 1/20 0.47
KDM4E B2RXH2 2/20 0.46
RGS12 O14924 1/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
APEX1 P27695 1/20 0.46
THPO P40225 1/20 0.46
BLM P54132 1/20 0.46
GNAI1 P63096 1/20 0.46
PMP22 Q01453 1/20 0.46
HIF1A Q16665 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CA3 P07451 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11398795 0.85 CA2 (0.53) CA2KDM4ERGS12LMNAPOLB
SCHEMBL29718749 0.84 CA2 (0.52) CA2KDM4ELMNAPOLBALDH1A1
SCHEMBL1115081 0.84 CA2 (0.52) CA2KDM4ELMNAPOLBALDH1A1
SCHEMBL2066538 0.82 GAA (0.68) CA2MEP1BKDM4ERGS12LMNA
SCHEMBL30696810 0.82 GAA (0.68) CA2MEP1BKDM4ERGS12LMNA
SCHEMBL2734611 0.82 KDM4E (0.67) CA2KDM4ERGS12LMNAPOLB
SCHEMBL909104 0.79 CA2 (0.47) CA2KDM4ELMNAPOLBALDH1A1
SCHEMBL29468719 0.79 CA2 (0.47) CA2KDM4ELMNAPOLBALDH1A1
SCHEMBL3396522 0.79 PIK3CA (0.56) CA2TSHRPIK3CA
SCHEMBL19641588 0.79 CA2 (0.47) CA2KDM4ELMNAPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 CA2 2515/4885MEP1B 3027/4885KDM4E 1174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.